Extended data table 1:
Co-morbidities in the cohorts investigated.
| Exposure group | N | Co-morbidity | ||||
|---|---|---|---|---|---|---|
| None | Diabetes | Hypertension | Others | Not known | ||
| BNT162b2 2 doses | 31 | 18 | 2 | 7 | 10 | 0 |
| BNT162b2 3 doses | 25 | 13 | 0 | 3 | 2 | 8 |
| CoronaVac 2 doses | 30 | 18 | 1 | 5 | 9 | 0 |
| CoronaVac 3 doses | 30 | 20 | 3 | 3 | 8 | 0 |
| CoronaVac 2 doses + BNT162b2 | 30 | 23 | 2 | 2 | 6 | 0 |
| SARS-CoV-2 convalescent | 30 | 11 | 5 | 8 | 19 | 0 |
| SARS-CoV-2 convalescent + 1 dose BNT162b2 | 30 | 14 | 5 | 6 | 15 | 0 |
| SARS-CoV-2 convalescent + 1 dose CoronaVac | 28 | 14 | 4 | 4 | 14 | 0 |
Individuals may have more than one co-morbidity.
Other: includes ischemic heart disease, hyperlipidaemia, renal disease, stroke, Thrombocytopenia, hepatitis B, hepatitis C, post renal transplant (n=1), hyperthyroidism, hypothyroidism, asthma, gout, dermatitis, TB, depression.